Allogene Therapeutics ALLO Payments For Leasing Costs Commissions And Tenant Improvements
Payments For Leasing Costs Commissions And Tenant Improvements at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's payments for leasing costs commissions and tenant improvements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's payments for leasing costs commissions and tenant improvements?
- Allogene Therapeutics (ALLO) reported payments for leasing costs commissions and tenant improvements of $3.23M in Q1 2026.
- How has Allogene Therapeutics's payments for leasing costs commissions and tenant improvements changed year-over-year?
- Allogene Therapeutics's payments for leasing costs commissions and tenant improvements increased by 0.2% year-over-year, from $3.23M to $3.23M.
- What is the long-term trend for Allogene Therapeutics's payments for leasing costs commissions and tenant improvements?
- Over 4 years (2021 to 2025), Allogene Therapeutics's payments for leasing costs commissions and tenant improvements has grown at a 21.1% compound annual growth rate (CAGR), from $6.01M to $12.92M.
- What does payments for leasing costs commissions and tenant improvements mean?
- This captures cash outflows related to tenant improvements, brokerage commissions, and other costs incurred to secure or prepare leased properties for use. These expenditures are distinct from routine rent payments and represent capital investments in physical infrastructure. It helps investors assess the cash intensity of the company's facility expansion strategy.